Skip to Content Facebook Feature Image

Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market

Business

Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market
Business

Business

Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market

2026-02-24 22:00 Last Updated At:22:15

A strategic combination of the Florida SMA hub, Benco Dental's network, SCHEU alliance, and FUGO's multi-resin platform drives a global scale-up.

  • Florida Production Hub: Establishing a domestic manufacturing base to provide localized, order-based SMA solutions for U.S. clinicians.
  • Benco Dental Partnership: Unlocking a massive distribution network covering over 30,000 dental offices (23% of the U.S. market).
  • Strategic Alliance with SCHEU Group: Partnering with Germany's century-old industry leader to validate SMA technology and expand European market share.
    Introducing SMA mass production and 'Simultaneous Multi-Resin Printing' for monolithic full dentures via the FUGO centrifugal 3D printing platform.

NEW YORK and SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Specialized in 3D printing–based smart materials, Graphy Inc. (KOSDAQ: 318060, CEO Unseob Sim) designated 2026 as the company's "Inaugural Year for U.S. Market Leadership" at LMT Lab Day 2026 and CDS 2026, held in Chicago from February 19 to 21. Building on a three-dimensional strategy that combines domestic production infrastructure, access to Tier-1 distribution networks, and proven technological reliability, Graphy is positioning itself as a definitive game-changer in the global clear aligner market.

Advancing into the U.S. Market: Delaware Subsidiary and Florida SMA Production Hub

The United States represents the world's largest orthodontic market, with over six million new patients annually. Following the establishment of its Delaware subsidiary in September 2025, Graphy is now constructing an SMA-dedicated central lab and order-based production facility in Florida. This hub will provide an integrated "one-stop" service—from digital treatment planning to final appliance fabrication—within the U.S. By leveraging this domestic base, Graphy aims to secure more than 200 key clinic accounts in the second half of 2026, accelerating the localized adoption of SMA technology.

Benco Dental: Unlocking a Strategic Access to 23% of U.S. Dental Offices

A cornerstone of Graphy's U.S. strategy is its new partnership with Benco Dental, the largest independent dental distributor in the United States. Benco serves over 30,000 clinics, representing approximately 23% of all U.S. dental offices. Through this alliance, Graphy's shape-memory materials, comprehensive resin portfolio, and specialized equipment will gain immediate access to the mainstream market, utilizing Benco's nationwide logistics network as a high-speed distribution "highway."

Alliance with SCHEU Group: The Apex of Technical Credibility

Graphy also announced a landmark partnership with Germany's SCHEU Group (SCHEU-DENTAL / Smile Dental), which celebrates its centennial in 2026. As a global benchmark for orthodontic technical standards, SCHEU Group's adoption of Graphy's SMA serves as a powerful validation of the material's stability and precision. This agreement transcends a simple distribution deal; it represents formal recognition of Graphy's innovation by one of Europe's most trusted partners. Industry observers anticipate that combining SCHEU's century-long brand equity with Graphy's disruptive technology will drive a significant surge in European market share.

FUGO Platform: Revolutionary 'Simultaneous Multi-Resin' Printing

At the same event, Graphy showcased its collaboration with U.S.-based FUGO Precision 3D, demonstrating the superior performance of centrifugal 3D printing. The FUGO platform achieved ultra-precise control at the 10-micron level, producing "layer-less" surfaces with crystal-clear transparency that surpasses conventional 3D printing standards.

The highlight of the demonstration was the "Simultaneous Multi-Resin Printing" for monolithic full dentures. While traditional methods require separate printing and manual bonding of teeth and gingiva, Graphy's material science combined with FUGO's platform enables the fabrication of a single-piece denture in one print. This assembly-free process reduces labor requirements by over 80%, effectively delivering a manufacturing revolution for digital prosthetics.

A Graphy spokesperson commented, "The synergy between SCHEU's 100-year legacy, Benco's Tier-1 distribution power, and FUGO's innovative production solutions will dramatically accelerate the clinical adoption of our SMA and digital prosthetic platforms. By delivering execution-driven results in the U.S. market, we will maximize shareholder value and solidify our momentum for global expansion."

About Graphy Inc.

Graphy Inc. (KOSDAQ: 318060, CEO Unseob Sim), is a Seoul-based advanced materials company specializing in 3D-printed shape-memory photopolymer resins for orthodontics and digital dentistry.
As the pioneer of Shape Memory Aligners (SMA), Graphy enables body-temperature-activated orthodontic appliances that deliver consistent, biologically optimized forces.

By combining scientific rigor, proprietary materials, and strategic global partnerships, Graphy is building a scalable platform for next-generation digital dental manufacturing, serving clinicians, laboratories, and enterprise partners worldwide. 

- Media & Investor Relations

Graphy Inc.
Ace Gasan ForHu, 6F, 225 Gasan Digital 1-ro, Geumcheon-gu, Seoul
sales@itgraphy.com 
https://www.itgraphy.com 
https://www.graphysma.com/about 

- SNS

https://www.linkedin.com/company/itgraphy/

https://www.instagram.com/graphy_global/

https://www.facebook.com/graphyinc/

https://www.facebook.com/GraphyUnitedStates

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market

Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market

Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market

Graphy Accelerates U.S. Expansion, Positioning Shape Memory Aligners (SMA) at the Forefront of the Global Orthodontic Market

HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by providing GMP manufacturing and distribution services for the radiotherapeutic drug product, after successfully developing and qualifying the radiolabeling process and analytical methods using a phase-appropriate approach that expedited IND filing.

The Phase 1/2a clinical study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu‑BetaBart, while also determining the recommended dose for future studies. 177Lu-BetaBart (RV‑01) is a 177Lutetium‑conjugated monoclonal antibody engineered to target the 4Ig isoform of B7‑H3, an immune checkpoint molecule overexpressed across multiple solid tumor types.

"Enabling the first patient dose of 177Lu-BetaBart reflects what matters most to us, ensuring that high‑quality radiopharmaceuticals are manufactured, released, and delivered on time so patients can access innovative therapies without delay," said Bruno Paquin, Chief Executive Officer of AtomVie. "Our team is deeply focused on operational excellence and reliability, supporting our partners from early clinical development through global supply."

"Dosing the first patient in the Phase 1/2a clinical study of 177Lu‑BetaBart represents an important milestone for Radiopharm Theranostics," said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. "We appreciate AtomVie's manufacturing expertise and commitment to quality as we advance BetaBart for patients with aggressive and difficult‑to‑treat solid tumors."

About BetaBart (RV-01)

RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. 177Lu-BetaBart is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with BetaBart have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent.

About the Phase 1/2a Clinical Trial

The FIH Phase 1/2a study (NCT07189871) is designed to establish the safety profile, biodistribution, pharmacokinetics, and radiation dosimetry of 177Lu-Betabart . The study aims to enroll 61 eligible participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal squamous cell carcinoma.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm Theranostics is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

For more information, please contact:
Riccardo Canevari, CEO & Managing Director
Phone number: +1 862 309 0293
e-mail id: rc@radiopharmtheranostics.com

About AtomVie(AtomVie)

AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently building and commissioning a new state-of-art, purpose-built 72,300 sq ft facility, set for operational readiness in H2 2026. For additional details visit our website https://www.atomvie.com/

For more information, please contact:
Tina Chainani, Business Development Manager
Phone number: +1 437 239 1288
e-mail id: tina.chainani@atomvie.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

Recommended Articles